Reducing Many forms of cancer as soon as possible
Mankind never ceases to cause some great advancement in technology. To make it more efficient, technology has gone to great lengths in order to create drugs contained in capsules or tablets. The difficult to treat diseases of the past years have now been found a solution. Suffering from common cold? There is really no need to fretting about it. This can just be solved by over-the-counter drugs and lots of fluids and rest. What can be done to alleviate stomachaches? There are lots of drugs available for this and one just have to choose which one works best. After a couple of hours, the ache in the stomach will surely go away. The pain felt when having those conditions is nothing compared to a person who has cancer. PARP inhibitors have been making that noise in the medical field lately. It would be appropriate to define first what a PARP inhibitor is.
PARP is just the short version for poly (ADP-ribose) polymerase. It is one of the proteins being used by the body. This protein contributes to the proper functioning of the body by fixing any damages in a cell’s DNA. Everyday, the body encounters stress and foreign bodies and this can greatly impact the cells. The worst that can happen is that no cell regeneration will occur without the presence of these proteins. If PARP is being inhibited, the obvious result is that it can not perform its task of repairing damaged DNA’s. If such thing is possible for normal cells, then probably the same mechanism will be valid for cancer cells. The regeneration of such cancer cells will be minimized or completely stopped. The result would then be the reduction of cancer cells and its further damaging effects to healthy cells.
Remember, this drug is still going under experimentation. This process is referred to as clinical trials. After the patients ingest the drug, scientists jot down the outcome. They are careful to consider not only the positive effects, but also the negative ones. The drug is currently aimed at treating breast, ovarian, and prostate cancer.
It is kind of hard understanding the nature of PARP inhibitors if medical terms are used to explain it. The word poly (ADP-ribose) polymerase itself is kind of difficult to comprehend. The three below are the types of inhibitors that one can find and are made comprehendible for one to have a better grasp of the concept :
. Veliparib
. Olaparib
. Iniparib
. Rucaparib
The above names are specific brands of inhibitors. Each drug brand targets different forms of cancers, but in reality they basically perform the same duty. Also, each of them comes from an unique company. Olaparib is one type of PARP inhibitor which is alternatively called AZD2281 and KU-0059436. This drug concentrates on the treatment of kinds of ovarian, breast, and prostate cancers. A company in London, England, United Kingdom by the name of Astra Zeneca is its main developer. This drug has been through Phase I trials and is working on Phase II trials. AG 014699, usually recognized as Rucaparib, is one other type of the four PARP inhibitors. In Phase I, it treated solid tumors. At this time, it’s used to treat ovarian and breast cancers for Phase II. Rucaparib was created by Pfizer, which is headquartered in New York City, New York, USA.
From the four brands of PARP inhibitors is one called Iniparib. BSI 201 is it’s other name, and it is mainly for breast cancers. It has already finished Phase I and Phase II clinical trials, which means it is now at Phase III. Sanofi is the name of the pharmaceutical company based in Paris, France that is behind Iniparib. Veliparib (ABT888) is the last kind of mainstream PARP inhibitor. It’s currently working on both Phase I and Phase II clinical trials. Phase I is dedicated to treating solid tumors. For Phase II, they’re focusing on breast cancers. Abbott Laboratories, located in Chicago, Illinois, USA, is the company developing Veliparib.
There are plenty of advancements in medicine. One simple illustration could be the parp inhibitors discovery.
Processing your request, Please wait....
